Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lunai Bioworks ( (LNAI) ) is now available.
On February 6, 2026, Lunai Bioworks Inc. received notice from Nasdaq’s Listing Qualifications Staff that its securities were subject to delisting, following earlier disclosures that the company faced potential removal from the exchange. The company promptly appealed and, on February 17, 2026, was informed that a Nasdaq Hearings Panel had granted its request for a hearing, scheduled for March 26, 2026, which temporarily stays the delisting decision.
The pending hearing leaves Lunai Bioworks’ Nasdaq status uncertain, as there is no assurance the panel will approve continued listing or that the company will regain and maintain full compliance with Nasdaq’s ongoing requirements. This situation introduces heightened risk for shareholders, as the outcome could affect the stock’s trading venue, liquidity profile, and the company’s visibility in public capital markets.
More about Lunai Bioworks
Lunai Bioworks Inc. is a publicly traded company whose securities are listed on the Nasdaq Stock Market. The firm operates within the broader biotechnology and life sciences investment universe, where continued listing status is important for liquidity, investor access, and institutional participation in its shares.
Average Trading Volume: 1,107,336
Technical Sentiment Signal: Sell
Current Market Cap: $14.15M
For detailed information about LNAI stock, go to TipRanks’ Stock Analysis page.